July 18th 2022
Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.
July 11th 2022
Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.
Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.
July 4th 2022
A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.
Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.
June 29th 2022
Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.
June 27th 2022
Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.
Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.
June 22nd 2022
Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.
A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.
June 15th 2022
Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.
Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.
June 8th 2022
Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.
Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.
June 1st 2022
Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.
Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.
May 26th 2022
Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.
Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.
May 19th 2022
Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.
Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.